Abstract
The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis. Receptor Activator of Nuclear Factor Kappa- B Ligand (RANKL) belongs to the TNF family and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Malfunction among RANK/RANKL/OPG can also result in bone loss diseases, including postmenopausal osteoporosis, rheumatoid arthritis, bone metastasis and multiple myeloma. To disrupt the unwanted functions of TNF and RANKL, current attempts focus on blocking TNF and RANKL binding to their receptors. In this review, we present the research efforts toward the development of low-molecular-weight pharmaceuticals that directly block the detrimental actions of TNF and RANKL.
Keywords: Tumor Necrosis Factor (TNF), osteoprotegerin (OPG), postmenopausal osteoporosis, rheumatoid arthritis, disease, metastasis.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Volume: 18 Issue: 8
Author(s): Georgia Melagraki, Georgios Leonis, Evangelos Ntougkos, Vagelis Rinotas, Christos Papaneophytou, Thomas Mavromoustakos, George Kontopidis, Eleni Douni, George Kollias*Antreas Afantitis*
Affiliation:
- Division of Immunology, Biomedical Sciences Research Center `Alexander Fleming`, Vari,Greece
- Division of Immunology, Biomedical Sciences Research Center `Alexander Fleming`, Vari,Greece
Keywords: Tumor Necrosis Factor (TNF), osteoprotegerin (OPG), postmenopausal osteoporosis, rheumatoid arthritis, disease, metastasis.
Abstract: The overexpression of Tumor Necrosis Factor (TNF) is directly related to the development of several autoimmune diseases, such as rheumatoid and psoriatic arthritis, inflammatory bowel disease, Crohn's disease, refractory asthma, and multiple sclerosis. Receptor Activator of Nuclear Factor Kappa- B Ligand (RANKL) belongs to the TNF family and is the primary mediator of osteoclast-induced bone resorption through interaction with its receptor RANK. The function of RANKL is physiologically inhibited by the action of osteoprotegerin (OPG), which is a decoy receptor that binds to RANKL and prevents the process of osteoclastogenesis. Malfunction among RANK/RANKL/OPG can also result in bone loss diseases, including postmenopausal osteoporosis, rheumatoid arthritis, bone metastasis and multiple myeloma. To disrupt the unwanted functions of TNF and RANKL, current attempts focus on blocking TNF and RANKL binding to their receptors. In this review, we present the research efforts toward the development of low-molecular-weight pharmaceuticals that directly block the detrimental actions of TNF and RANKL.
Export Options
About this article
Cite this article as:
Melagraki Georgia , Leonis Georgios , Ntougkos Evangelos , Rinotas Vagelis , Papaneophytou Christos , Mavromoustakos Thomas , Kontopidis George , Douni Eleni , Kollias George *, Afantitis Antreas*, Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL), Current Topics in Medicinal Chemistry 2018; 18 (8) . https://dx.doi.org/10.2174/1568026618666180607084430
DOI https://dx.doi.org/10.2174/1568026618666180607084430 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Condensed and Hydrolysable Tannins as Antioxidants Influencing the Health
Mini-Reviews in Medicinal Chemistry Potential Targets for Anti-Inflammatory and Anti-Allergic Activities of Marine Algae: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Kinase Chemogenomics: Targeting the Human Kinome for Target Validation and Drug Discovery
Mini-Reviews in Medicinal Chemistry Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular Research Correlations and Influence of TAP2 Genes Polymorphisms and Systemic Lupus Erythematosus Propensity
Current Rheumatology Reviews Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Substance P in Rheumatic Diseases
Current Rheumatology Reviews Incidence and Prevention of Thromboembolic Events in One Stage Bilateral Total Hip Arthroplasty: A Systematic Review
Current Vascular Pharmacology Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Natural and Induced Antibody Polyreactivity
Anti-Cancer Agents in Medicinal Chemistry New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews